Compare EDIT & EVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDIT | EVH |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.8M | 469.0M |
| IPO Year | 2016 | 2015 |
| Metric | EDIT | EVH |
|---|---|---|
| Price | $2.79 | $5.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $5.30 | ★ $7.93 |
| AVG Volume (30 Days) | ★ 2.7M | 2.3M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $31,937,000.00 | ★ $907,957,000.00 |
| Revenue This Year | N/A | $33.89 |
| Revenue Next Year | N/A | $15.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 132.64 | N/A |
| 52 Week Low | $1.66 | $2.10 |
| 52 Week High | $4.54 | $11.92 |
| Indicator | EDIT | EVH |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 69.28 |
| Support Level | $2.77 | $3.67 |
| Resistance Level | $3.27 | $8.30 |
| Average True Range (ATR) | 0.20 | 0.33 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 70.16 | 91.33 |
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.